Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東新華製藥股份有限公司

Shandong Xinhua Pharmaceutical Company Limited

(a joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 00719)

(I) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING (II) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND EXECUTIVE DIRECTORS

The board (the "**Board**") of directors (the "**Directors**") of Shandong Xinhua Pharmaceutical Company Limited (the "**Company**") is pleased to announce that all resolutions proposed have been duly passed at the extraordinary general meeting (the "**EGM**") held in sequence on the date of this announcement at the Company's conference room at No. 1 Lutai Ave., Hi-tech District, Zibo City, Shandong Province, the PRC.

The details of the resolutions considered at the Meetings were set out in the notices of extraordinary general meeting dated 29 September 2022 and the circular dated 29 September 2022 of the Company (the "**Circular**"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Circular.

As at the date of the EGM, the total number of issued Shares of the Company was 669,627,235 Shares, of which 474,627,235 Shares were A Shares and 195,000,000 were H Shares.

ATTENDANCE AT THE EGM AND THE POLL RESULTS

ATTENDANCE AT THE EGM

The attendance results of the EGM were as follows:

Number of S	15	
person or by p	roxies) or by way of network voting	
Including:	total number of A Shareholders who attended the EGM on-	1
	Site	
	total number of H Shareholders who attended the EGM on-	1
	site	

	total number of A Shareholders who participated in network	13
	voting	
Total number site (whether voting	209,933,134	
Including:	total number of voting A Shares held by Shareholders who attended the EGM on-site	204,864,092
	total number of voting H Shares held by Shareholders who attended the EGM on-site	3,247,798
	total number of voting A Shares held by the Shareholders who participated in network voting	1,821,244
	f the total number of voting Shares of the participating (whether in person or by proxies) to the total number of	31.35%
Including:	percentage of the total number of voting A Shares of the Shareholders who attended the EGM on-site to the total number of issued Shares	30.59%
	percentage of the total number of voting H Shares of the Shareholders who attended the EGM on-site to the total number of issued Shares	0.49%
	percentage of the total number of voting A Shares of the A Shares Shareholders who participated in network voting to the total number of issued Shares	0.27%

So far as the Company is aware, no other Shareholder was required to abstain from voting in respect of any of the resolutions proposed at the EGM under the Listing Rules. The Company is not aware of any parties having indicated in the Circular their intention to vote against any resolutions proposed at the EGM or to abstain. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of any resolution at the EGM as set out under Rule 13.40 of the Listing Rules.

The total numbers of Shares entitling the Shareholders to attend and vote for or against the ordinary resolutions proposed at the EGM were therefore 669,627,235 Shares, representing approximately 100% of the Shares respectively as at the day of this announcement.

The Company would like to report that the following:

Mr. He Tongqing, Mr. Xu Lie and Mr. Cong Kechun attended the EGM in person; and

Mr. Pan Guangcheng, Mr. Zhu Jianwei and Mr. Lo Wah Wai were unable to attend the EGM due to the COVID-19-related travel restrictions in the PRC or other business engagement.

POLL RESULTS OF THE EGM

	Resolution	Total number of votes (%)					
No.		For	Against	Abstained	— Voting results		
		ORDINAR	Y RESOLUTIONS				
1.	To consider and approve the appointment of Mr. Ling Peixue as an independent-non executive director of the Company for a term concurrent with the tenth session of the Board (the " Tenth Session of the Board") until 22 December 2023.						
		209,919,434 Shares	13,700 Shares	0 Shares	Pass		
		(99.99%)	(0.01%)	(0%)			
2.	To consider and approve the appointment of Mr. Xu Wenhui as executive director of the Company by cumulative voting for a term concurrent with the Tenth Session of the Board until 22 December 2023						
		209,879,847 Shares	0 Shares	0 Shares	Pass		
		(99.97%)	(0%)	(0%)			
3.	To consider and approve the appointment of Mr. Hou Ning as executive director of the Company by cumulative voting for a term concurrent with the Tenth Session of the Board until 22 December 2023.						
		209,879,837 Shares	0 Shares	0 Shares	Pass		
		(99.97%)	(0%)	(0%)			

Note: the percentages shown were rounded to the nearest 2 decimal places. The numbers may not add up to 100% due to the rounding.

As more than one-half of the votes from the Shareholders who were entitled to attend and who voted at the EGM were cast in favour of the ordinary resolutions, all resolutions have been duly passed at the EGM.

ATTESTATION BY LAWYER AND SCRUTINEER

ShineWing Certified Public Accountants (Special General Partnership ("ShineWing"), the auditors of the Company, served as the scrutineer at the Meetings for the purpose of vote taking.

The Meetings were attested by JINGTIAN & GONGCHENG, PRC legal advisers to the Company, which issued a written legal opinion certifying that the convening and procedures of the Meetings, the qualifications of the attendees and the voting procedures were in compliance with Corporate Law of the People's Republic of China (中華人民共和國公司法), the Security Law of the People's Republic of China (中華人民共和國公司法), the Security Law of the People's Republic of China (中華人民共和國公司法), the Security Law of Listed Companies (上市公司股東大會規則), Rules for General Meetings of Shareholders of Listed Companies of Shenzhen Stock Exchange (深圳證券交易所上市公司股東大會網路投票細則) and other relevant laws, administrative regulations and rules and the Company's Articles of Association. The qualifications of the Convener and the attendees were legal and valid.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND EXECUTIVE DIRECTORS

Reference are made to the announcement of the Company dated 30 August 2022, 19 September 2022 and the Circular in relation to the proposed appointments of (i) Mr. LING Peixue ("**Mr. Ling**") as an independent non-executive director of the Company, (ii) Mr. Xu Wenhui ("**Mr. Xu**") as an executive director of the Company and (iii) Mr. Hou Ning ("**Mr. Hou**") as an executive director of the Company (the "**Appointments**").

The Board hereby announces that, the Appointments have been approved at the EGM. The biographical details of each of the Appointments are set out in the Circular.

Mr. Ling formally serves as an independent non-executive director of the Company from the date of this announcement (i.e. 27 October 2022) to the expiration date of the term of office of the Tenth Session of the Board until 22 December 2023. In addition, each of Mr. Xu and Mr. Hou formally serves as an executive director of the Company from the date of this announcement (i.e. from 27 October 2022) to the expiration date of the term of office of the Tenth Session of the Board until 22 December 2023.

By Order of the Board

Shandong Xinhua Pharmaceutical Company Limited He Tongqing Chairman

27 October 2022, Zibo, PRC

As at the date of this announcement, the Board comprises:

Executive Directors: Mr. He Tongqing (*Chairman*) Mr. Xu Wenhui Mr. Hou Ning

Non-executive Directors: Mr. Xu Lie Mr. Cong Kechun Independent non-executive Directors: Mr. Pan Guangcheng Mr. Zhu Jianwei Mr. Lo Wah Wai Mr. Ling Peixue